Novartis | NVS - PE Price to Earnings


Novartis reported 21.54 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Amgen 18.6 0.53 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
Bausch Health Companies 2.48 10.37 Sep/2026
Biogen 29.15 5.92 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Corcept Therapeutics 86.2 102.04 Sep/2026
Drreddys Laboratories 28.78 9.53 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Glaxosmithkline 15.17 0.08 Sep/2026
J&J 25.86 3.57 Sep/2026
Merck 34.36 2.11 Sep/2026
Novartis 19.17 3.24 Sep/2026
Novartis 21.54 0.18 Sep/2026
Pacira 80.9 45.22 Sep/2026
Perrigo 21.11 6.34 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Phibro Animal Health 13.82 4.04 Dec/2025
Prestige Brands 11.89 3.75 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 22.34 3.38 Sep/2026
Sanofi 21.74 11.35 Sep/2026
Supernus Pharmaceuticals 72.26 6.89 Sep/2026
Zoetis 11.38 0.8 Sep/2026